Published in Inflamm Bowel Dis on December 01, 2013
Real life clinic visits do not match the ideals of shared decision making. J Pediatr (2014) 0.93
Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease. Inflamm Bowel Dis (2014) 0.75
Risk assessment in Crohn's disease. Gastroenterol Hepatol (N Y) (2014) 0.75
Parents' information needs and influential factors when making decisions about TNF-α inhibitors. Pediatr Rheumatol Online J (2016) 0.75
Patient decision tools in inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2013) 0.75
In the pipeline. Gastroenterol Hepatol (N Y) (2014) 0.75
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev (2011) 9.75
Inflammatory bowel disease. N Engl J Med (2009) 8.62
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49
Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med (2009) 7.53
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39
Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis (2010) 3.55
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology (2006) 3.32
Regulatory T cells reinforce intestinal homeostasis. Immunity (2009) 3.27
Mucosal healing in inflammatory bowel diseases: a systematic review. Gut (2012) 3.02
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol (2009) 2.72
Health literacy and child health outcomes: a systematic review of the literature. Pediatrics (2009) 2.61
Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol (2003) 2.58
The competency of children and adolescents to make informed treatment decisions. Child Dev (1982) 2.53
Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis (2011) 2.46
Option Grids: shared decision making made easier. Patient Educ Couns (2012) 2.33
The health literacy of parents in the United States: a nationally representative study. Pediatrics (2009) 2.13
The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol (2003) 2.06
Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology (2009) 2.00
Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol (2003) 1.77
Assessment of knowledge in adolescents with inflammatory bowel disease using a novel transition tool. Inflamm Bowel Dis (2010) 1.68
Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology (1988) 1.67
Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr (2000) 1.63
A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. J Pediatr Gastroenterol Nutr (2003) 1.57
Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr (2004) 1.55
A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2010) 1.55
Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr (2004) 1.52
Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr (2012) 1.52
Longitudinal growth in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr (1994) 1.44
Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.42
Health care preferences and priorities of adolescents with chronic illnesses. Pediatrics (2004) 1.34
Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology (2010) 1.32
Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut (2011) 1.24
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol (2012) 1.22
Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol (2011) 1.16
Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol (2010) 1.14
Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther (2008) 1.14
Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis (2009) 1.13
Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.13
Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal (2008) 1.13
Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr (2007) 1.13
Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr (2004) 1.11
Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol (2005) 1.08
Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology (2012) 1.07
Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol (2009) 1.07
Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis (2007) 1.06
Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis (2004) 1.04
Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol (2000) 1.03
Perceived barriers to care and attitudes towards shared decision-making among low socioeconomic status parents: role of health literacy. Acad Pediatr (2012) 1.02
The role of parent health literacy among urban children with persistent asthma. Patient Educ Couns (2009) 1.01
Infliximab in pediatric Crohn disease patients with enterovesicular fistulas. J Pediatr Gastroenterol Nutr (2007) 1.01
Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis (2011) 0.99
Course and treatment of perianal disease in children newly diagnosed with Crohn's disease. Inflamm Bowel Dis (2009) 0.97
Increasing incidence of pediatric inflammatory bowel disease in Spain (1996-2009): the SPIRIT Registry. Inflamm Bowel Dis (2013) 0.96
Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther (2003) 0.96
Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther (2003) 0.96
Views of treatment decision making from adolescents with chronic illnesses and their parents: a pilot study. Health Expect (2008) 0.95
Strategies to improve quality of life in adolescents with inflammatory bowel disease. Inflamm Bowel Dis (2009) 0.95
A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther (2011) 0.94
Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis (2009) 0.93
Identifying youth nonadherence in clinical settings: data-based recommendations for children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis (2011) 0.93
Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis (2004) 0.92
Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis (2005) 0.92
Clinicians poorly assess health literacy-related readiness for transition to adult care in adolescents with inflammatory bowel disease. Clin Gastroenterol Hepatol (2012) 0.91
Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis (2005) 0.90
The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease. Eur J Gastroenterol Hepatol (2012) 0.90
Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. Clin Gastroenterol Hepatol (2008) 0.90
Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis (2011) 0.89
Efficacy of early treatment with infliximab in pediatric Crohn's disease. World J Gastroenterol (2010) 0.89
Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol (2002) 0.89
The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited. Aliment Pharmacol Ther (2010) 0.88
Improvement in growth of children with Crohn disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr (2011) 0.88
Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis (2011) 0.87
Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis (2008) 0.87
Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2004) 0.87
Sixty-year study of incidence of childhood ulcerative colitis finds eleven-fold increase beginning in 1990s. Inflamm Bowel Dis (2013) 0.87
Infliximab for ulcerative colitis in children and adolescents. J Clin Gastroenterol (2008) 0.86
Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease. J Gastroenterol Hepatol (2010) 0.86
Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort. Inflamm Bowel Dis (2011) 0.86
Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality. Am J Gastroenterol (2010) 0.85
Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs (2007) 0.85
Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr (2002) 0.85
Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. Dig Liver Dis (2008) 0.85
Infliximab therapy in children with Crohn's disease: a one-year evaluation of efficacy comparing 'top-down' and 'step-up' strategies. Acta Paediatr (2011) 0.84
Children's knowledge and degree of participation in decision making when undergoing a clinical diagnostic procedure. Pediatr Nurs (2008) 0.83
Infliximab dependency in a national cohort of children with Crohn's disease. J Pediatr Gastroenterol Nutr (2006) 0.83
Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr (2004) 0.83
Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am J Gastroenterol (2009) 0.83
Adalimumab treatment in children with refractory Crohn's disease. Dig Dis Sci (2009) 0.82
Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr (2009) 0.81
Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn' disease. Dig Dis Sci (2007) 0.81
12-month follow-up after successful infliximab therapy in pediatric crohn disease. J Pediatr Gastroenterol Nutr (2008) 0.80
Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin (2011) 0.80
Making therapeutic decisions in inflammatory bowel disease: the role of patients. Curr Opin Gastroenterol (2009) 0.79
Safety and efficacy of adalimumab in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr (2008) 0.79
Cardiac involvement in children with IBD during infliximab therapy. Inflamm Bowel Dis (2006) 0.78
Prevention of acute adverse events related to infliximab infusions in pediatric patients. Arthritis Care Res (Hoboken) (2010) 0.77
Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet (2011) 5.58
Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet (2010) 4.65
Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol (2006) 2.97
Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care (2009) 2.36
Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. Clin Gastroenterol Hepatol (2004) 2.24
Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol (2006) 2.06
An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index. Inflamm Bowel Dis (2014) 2.05
Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol (2005) 1.93
Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr (2007) 1.74
Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology (2007) 1.71
Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2012) 1.57
Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2006) 1.49
Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBD. Inflamm Bowel Dis (2008) 1.47
Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis (2010) 1.42
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
Significant variation in recommendation of care for women of reproductive age with ulcerative colitis postileal pouch-anal anastomosis. Dig Dis Sci (2014) 1.40
Isolated asymptomatic ileitis does not progress to overt Crohn disease on long-term follow-up despite features of chronicity in ileal biopsies. Am J Surg Pathol (2009) 1.29
Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 1.24
Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol (2012) 1.23
Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey. Inflamm Bowel Dis (2009) 1.19
The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol (2011) 1.15
A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2014) 1.15
Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal (2008) 1.13
A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD. Inflamm Bowel Dis (2013) 1.12
Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm (2010) 1.11
Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists. Clin Gastroenterol Hepatol (2008) 1.08
A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis (2004) 1.07
Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis (2014) 1.05
Quality improvement in inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2013) 1.00
Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis (2013) 1.00
Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflamm Bowel Dis (2011) 0.99
Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda. Inflamm Bowel Dis (2013) 0.97
The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastroenterol Hepatol (2010) 0.95
Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm Bowel Dis (2006) 0.94
Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis (2014) 0.94
Improving quality of care in IBD: a STEEEP challenge. Inflamm Bowel Dis (2010) 0.90
The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey. Dig Dis Sci (2009) 0.89
Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor α agents for inflammatory bowel disease. Gastroenterol Clin North Am (2012) 0.88
Association of Mycobacterium avium subspecies paratuberculosis with Crohn Disease in pediatric patients. J Pediatr Gastroenterol Nutr (2011) 0.88
Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol (2004) 0.87
Patient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease. Digestion (2009) 0.87
Variants in ZNF365 isoform D are associated with Crohn's disease. Gut (2011) 0.87
Embracing the internet for progress in shared decision-making. Inflamm Bowel Dis (2007) 0.87
Disease perceptions among people with Crohn's disease. Inflamm Bowel Dis (2008) 0.86
The inflammatory bowel disease live interinstitutional and interdisciplinary videoconference education (IBD LIVE) series. Inflamm Bowel Dis (2014) 0.86
Should rare complications of treatment influence decision-making in ulcerative colitis? Inflamm Bowel Dis (2007) 0.86
A new tool to measure the burden of Crohn's disease and its treatment: do patient and physician perceptions match? Inflamm Bowel Dis (2010) 0.85
Knowledge, Attitudes, and Beliefs Regarding the Role of Nutrition in IBD Among Patients and Providers. Inflamm Bowel Dis (2016) 0.84
Video capsule endoscopy impacts decision making in pediatric IBD: a single tertiary care center experience. Inflamm Bowel Dis (2013) 0.83
Implementing quality measures for inflammatory bowel disease. Curr Gastroenterol Rep (2015) 0.82
Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies. J Clin Pharmacol (2015) 0.80
Is chronic pain an extraintestinal manifestation of IBD? Inflamm Bowel Dis (2009) 0.80
Accidentally ASCENDing into comparative effective research for inflammatory bowel disease. Gastroenterology (2009) 0.78
Severe colitis in children. J Pediatr Gastroenterol Nutr (2005) 0.78
Increasing Patient Activation Could Improve Outcomes for Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis (2015) 0.78
Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy. Arch Pathol Lab Med (2004) 0.78
Patients with Crohn's Disease Are More Likely to Remain on Biologics than Immunomodulators: A Meta-Analysis of Treatment Durability. Dig Dis Sci (2015) 0.78
Foam preparations for the treatment of ulcerative colitis. Curr Drug Deliv (2012) 0.77
Distinct phenotypes of children with perianal perforating Crohn's disease. J Pediatr Surg (2013) 0.77
Inflammatory bowel disease-patients are insufficiently educated about the basic characteristics of their disease and the associated risk of colorectal cancer. Dig Liver Dis (2010) 0.76
IBD LIVE Case Series-Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment? Inflamm Bowel Dis (2015) 0.75
Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe Group. Gastroenterol Hepatol (N Y) (2008) 0.75
Give me prednisone and give me death. Inflamm Bowel Dis (2009) 0.75
Premedication Use Before Infliximab Administration: A Cross-sectional Analysis. Inflamm Bowel Dis (2017) 0.75
IBD LIVE case series-case 1: smoking, a controversial but effective treatment for ulcerative colitis. Inflamm Bowel Dis (2014) 0.75
Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis (2016) 0.75
Comparative effectiveness research in inflammatory bowel disease: prospects and challenges. Expert Rev Gastroenterol Hepatol (2012) 0.75
IBD LIVE Case Series-Case 6. Inflamm Bowel Dis (2016) 0.75
IBD LIVE Series-Case 8: Treatment Options for Refractory Esophageal Crohn's Disease and Hidradenitis Suppurativa. Inflamm Bowel Dis (2017) 0.75
Combination Therapy in Pediatric Inflammatory Bowel Disease: Yes, No, Maybe. Inflamm Bowel Dis (2017) 0.75
Using Therapeutic Drug Monitoring to Identify Variable Infliximab Metabolism in an Individual Patient With Ulcerative Colitis. J Clin Gastroenterol (2016) 0.75
Delivering High Value Inflammatory Bowel Disease Care Through Telemedicine Visits. Inflamm Bowel Dis (2017) 0.75
Probiotics in pediatric inflammatory bowel diseases. Curr Gastroenterol Rep (2009) 0.75
Self-efficacy and Resilience Are Useful Predictors of Transition Readiness Scores in Adolescents with Inflammatory Bowel Diseases. Inflamm Bowel Dis (2017) 0.75
The Evolving Role of Thiopurines for Inflammatory Bowel Disease. Inflamm Bowel Dis (2016) 0.75
A Web-based Multimedia Program Before Colonoscopy Increased Knowledge and Decreased Anxiety, Sedation Requirement, and Procedure Time. J Clin Gastroenterol (2017) 0.75
Evaluating Study Withdrawal Among Biologics and Immunomodulators in Treating Ulcerative Colitis: A Meta-analysis of Controlled Clinical Trials. Inflamm Bowel Dis (2016) 0.75
Assessment of Gaps in Care and the Development of a Care Pathway for Anemia in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis (2016) 0.75
Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications. Inflamm Bowel Dis (2016) 0.75
Patient-reported Anxiety: A Possible Predictor of Pediatric Inflammatory Bowel Disease Health Care Use. Inflamm Bowel Dis (2016) 0.75
Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel. Inflamm Bowel Dis (2016) 0.75
Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient-Physician Visits. Inflamm Bowel Dis (2017) 0.75
Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis. Inflamm Bowel Dis (2017) 0.75
IBD LIVE Case Series-Case 6: Persistent Skin Lesions in a Patient with Crohn's Disease: You Hear Hoof Beats and Discover a Zebra. Inflamm Bowel Dis (2016) 0.75
IBD LIVE Series-Case 7: The Brain-Gut Connection and the Importance of Integrated Care in IBD. Inflamm Bowel Dis (2017) 0.75
Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis. Inflamm Bowel Dis (2017) 0.75
TNFRSF1B Is Associated with ANCA in IBD. Inflamm Bowel Dis (2016) 0.75
IBD LIVE Case Series-Case 3: Very Early-Onset Inflammatory Bowel Disease: When Genetic Testing Proves Beneficial. Inflamm Bowel Dis (2015) 0.75
Observational Study of Perspectives of Inflammatory Bowel Disease Patients Concerning the Use of Corticosteroids. Dig Dis (2017) 0.75